Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130746 | 0.73 | HTR2C (0.40) | HTR2CNOS3NOS1NOS2HTR2A | |
| SCHEMBL4972049 | 0.73 | HTR2C (0.40) | HTR2CNOS3NOS1NOS2HTR2A | |
| SCHEMBL10474594 | 0.67 | — | — | |
| SCHEMBL1162920 | 0.67 | — | — | |
| SCHEMBL20863923 | 0.65 | ACHE (0.44) | HTR2CNOS3NOS1NOS2HTR2A | |
| SCHEMBL15147096 | 0.64 | HTR2A (0.57) | HTR2CHTR2AHTR2BPDPK1 | |
| SCHEMBL186363 | 0.64 | HTR2A (0.57) | HTR2CHTR2AHTR2BPDPK1 | |
| SCHEMBL217130 | 0.64 | HTR2A (0.31) | HTR2A | |
| SCHEMBL3543729 | 0.63 | TSHR (0.32) | — | |
| SCHEMBL30298332 | 0.63 | ALDH1A1 (0.43) | HTR2CNOS3NOS1NOS2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948649-B1 | FUNGICIDAL CARBOXAMIDES | DU PONT (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20100179118-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-7737167-B2 | 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| EP-2060563-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1998774-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES TO ENHANCE MEMORY FUNCTION | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-10 | — | — | EP | disclosed |
| EP-1776348-B1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH AS (DK) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007105177-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES TO ENHANCE MEMORY FUNCTION | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-20070197618-A1 | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| EP-1776348-A2 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006013210-A2 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | GRIN2A, BDNF, GRIN2C | HTR2C 88/4885NOS3 398/4885NOS1 382/4885 |
| US-20070197618-A1 | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | KCNN2, KCNN1, KCNN3 | HTR2C 1075/4885NOS3 2471/4885NOS1 3068/4885 |
| US-20100179118-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | HRH2, HRH1, HRH4 | HTR2C 173/4885NOS3 310/4885NOS1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.